MABN254
Anti-amyloid beta peptide (MOAB-2), pan Antibody, clone 6C3
clone 6C3, from mouse
Synonym(s):
Amyloid beta A4 protein, ABPP, APPI, APP, Alzheimer′s disease amyloid protein, cerebral vascular amyloid peptide, CVAP, PreA4, Protease nexin-II, PN-II
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
6C3, monoclonal
species reactivity
human
technique(s)
dot blot: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... APP(351)
General description
Pan-amyloid-beta (1-40) is one of several functional peptides (39 to 43 amino acids in length) formed from proteolytic cleavage of the amyloid-beta precursor protein (APP) by the family of secretase enzymes. Although the APP protein is required for a number of biological functions, including axonal transport, cell adhesion, and transcription, the Ab 1-40 peptide has been studied mostly for its potential to aggregate and form neurite plaques, which may contribute to neurotoxicity, particularly in the context of neurodegenerative disease such as Alzheimer’s. Previous studies have demonstrated that Anti-pan amyloid beta peptide (MOAB2), clone 6C3 detects specifically amyloid-beta, but not APP. Furthermore MOAB2 detects multiple amyloid-beta 40 and amyloid-beta 42 conformations including unaggregated, oligomeric and fibrillar. In a number of immunohistochemical and biochemical analyses, MOAB2 consistently detected intraneuronal amyloid-beta, but not APP, and showed greater specificity to amyloid-beta than 6E10. MOAB2 is therefore suitable for sensitive and specific detection of accumulating amyloid-beta peptides in Alzheimer’s disease models.
Specificity
This antibody recognizes amyloid-ß and not APP (amyloid precursor protein). Specifically, clone 6C3 recognizes unaggregated, oligomeric, and fibrillar forms of Aß42 and Aß40.
Immunogen
Linear peptide corresponding to human pan amyloid beta peptide (MOAB-2).
Application
Anti-amyloid beta peptide (MOAB-2), pan Antibody, clone 6C3 is an antibody against amyloid beta peptide (MOAB-2), pan, clone 6C3 for use in western blotting, IHC (Paraffin), Immunofluorescence, IP, Dot Blot.
Immunofluorescence Analysis: A 1:1,000 dilution from a representative lot detected Amyloid Beta Peptide in human Alzeimer′s diseased brain (see website for images).
Western Blot Analysis: A representative lot was used by an independent laboratory in unaggregated forms of Aß42 and Aß40. (Youmans, K.L., et al. (2012). Mol Neurodegener. 7;8.)
Dot Blot Analysis: Serial Aβ40 and Aβ42 dilutions were probed with MOAB-2 or 6E10 by an independent laboratory. (Youmans, K.L., et al. (2012). Mol Neurodegener. 7;8.)
Immunoprecipitationt Analysis: A representative lot was used by an independent laboratory in unaggregated and fibrillar forms of Aß42 and Aß40. (Youmans, K.L., et al. (2012). Mol Neurodegener. 7;8.)
Western Blot Analysis: A representative lot was used by an independent laboratory in unaggregated forms of Aß42 and Aß40. (Youmans, K.L., et al. (2012). Mol Neurodegener. 7;8.)
Dot Blot Analysis: Serial Aβ40 and Aβ42 dilutions were probed with MOAB-2 or 6E10 by an independent laboratory. (Youmans, K.L., et al. (2012). Mol Neurodegener. 7;8.)
Immunoprecipitationt Analysis: A representative lot was used by an independent laboratory in unaggregated and fibrillar forms of Aß42 and Aß40. (Youmans, K.L., et al. (2012). Mol Neurodegener. 7;8.)
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Quality
Evaluated by Immunohistochemistry in Alzheimer′s diseased human brain tissue.
Immunohistochemistry Analysis: A 1:1,000 dilution of this antibody detected Amyloid Beta Peptide in human Alzheimer′s diseased brain tissue.
Immunohistochemistry Analysis: A 1:1,000 dilution of this antibody detected Amyloid Beta Peptide in human Alzheimer′s diseased brain tissue.
Target description
4 kDa calculated but could be larger since clone 6C3 recognizes unaggregated, oligomeric, and fibrillar forms of Aß42 and Aß40.
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG2aλ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
Alzheimer′s diseased human brain tissue.
Alzheimer′s diseased human brain tissue.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xu Hou et al.
Frontiers in aging neuroscience, 7, 207-207 (2015-11-20)
Alzheimer's disease (AD), the most common form of dementia, disproportionately affects women in both prevalence and severity. This increased vulnerability to AD in women is strongly associated with age-related ovarian hormone loss and apolipoprotein E 4 allele (ApoE4), the most
Natalia A Muraleva et al.
Antioxidants (Basel, Switzerland), 9(8) (2020-08-01)
Alzheimer's disease (AD) is the most common type of dementia and is currently incurable, and mitogen-activated protein kinase (MAPK) p38 is implicated in the pathogenesis of AD. p38 MAPK inhibition is considered a promising strategy against AD, but there are
Cinzia Rinaldo et al.
Cancer research, 69(15), 6241-6248 (2009-07-30)
In the past few years, much effort has been devoted to show the single-target specificity of nongenotoxic, p53 reactivating compounds. However, the divergent biological responses induced by the different compounds, even in the same tumor cells, demand additional mechanistic insights
Nazanin Mirzaei et al.
Glia, 64(6), 993-1006 (2016-03-10)
Microglial activation has been linked with deficits in neuronal function and synaptic plasticity in Alzheimer's disease (AD). The mitochondrial translocator protein (TSPO) is known to be upregulated in reactive microglia. Accurate visualization and quantification of microglial density by PET imaging
Evidence for a protective effect of the loss of I?4-containing nicotinic acetylcholine receptors on AI?-related neuropathology in Tg2576 mice.
Vilella, et al.
Frontiers in Neuroscience, 17, 1097857-1097857 (2023)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service